Literature DB >> 24554303

Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.

Giovanni Rossi1, Maria Marta Minervini, Lorella Melillo, Francesco di Nardo, Chiara de Waure, Potito Rosario Scalzulli, Gianni Perla, Daniela Valente, Nicola Sinisi, Nicola Cascavilla.   

Abstract

In acute myeloid leukemia (AML), the detection of minimal residual disease (MRD) as well as the degree of log clearance similarly identifies patients with poor prognosis. No comparison was provided between the two approaches in order to identify the best one to monitor follow-up patients. In this study, MRD and clearance were assessed by both multiparameter flow cytometry (MFC) and WT1 expression at different time points on 45 AML patients achieving complete remission. Our results by WT1 expression showed that log clearance lower than 1.96 after induction predicted the recurrence better than MRD higher than 77.0 copies WT1/10(4) ABL. Conversely, on MFC, MRD higher than 0.2 % after consolidation was more predictive than log clearance below 2.64. At univariate and multivariate analysis, positive MRD values and log clearance below the optimal cutoffs were associated with a shorter disease-free survival (DFS). At the univariate analysis, positive MRD values were also associated with overall survival (OS). Therefore, post-induction log clearance by WT1 and post-consolidation MRD by MFC represented the most informative approaches to identify the relapse. At the optimal timing of assessment, positive MRD and log-clearance values lower than calculated thresholds similarly predicted an adverse prognosis in AML.

Entities:  

Mesh:

Year:  2014        PMID: 24554303     DOI: 10.1007/s00277-014-2029-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

Review 1.  Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Authors:  Peter H Wiernik
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

Review 2.  Minimal Residual Disease in Acute Myeloid Leukemia.

Authors:  Pamela J Sung; Selina M Luger
Journal:  Curr Treat Options Oncol       Date:  2017-01

3.  Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.

Authors:  Lijie Han; Yilu Li; Jiaying Wu; Jie Peng; Xiaolin Han; Hongmian Zhao; Chen He; Yuanyuan Li; Weimin Wang; Mengmeng Zhang; Yafei Li; Hui Sun; Haixia Cao; Li'na Sang; Zhongxing Jiang; Jifeng Yu
Journal:  Int J Hematol       Date:  2022-08-28       Impact factor: 2.319

4.  Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.

Authors:  Nicholas J Short; Chenqi Fu; Donald A Berry; Roland B Walter; Sylvie D Freeman; Christopher S Hourigan; Xuelin Huang; Graciela Nogueras Gonzalez; Hyunsoo Hwang; Xinyue Qi; Hagop Kantarjian; Shouhao Zhou; Farhad Ravandi
Journal:  Leukemia       Date:  2022-10-19       Impact factor: 12.883

5.  Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.

Authors:  Cong Yu; Qing-lei Kong; Yun-xiang Zhang; Xiang-qin Weng; Jing Wu; Yan Sheng; Chun-lei Jiang; Yong-mei Zhu; Qi Cao; Shu-min Xiong; Jun-min Li; Xiao-dong Xi; Sai-juan Chen; Bing Chen
Journal:  J Hematol Oncol       Date:  2015-05-10       Impact factor: 17.388

6.  Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.

Authors:  Michele Malagola; Cristina Skert; Erika Borlenghi; Marco Chiarini; Chiara Cattaneo; Enrico Morello; Valeria Cancelli; Federica Cattina; Elisa Cerqui; Chiara Pagani; Angela Passi; Rossella Ribolla; Simona Bernardi; Viviana Giustini; Cinzia Lamorgese; Giuseppina Ruggeri; Luisa Imberti; Luigi Caimi; Domenico Russo; Giuseppe Rossi
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

Review 7.  Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Authors:  Maria Ilaria Del Principe; Francesco Buccisano; Luca Maurillo; Giuseppe Sconocchia; Mariagiovanna Cefalo; Maria Irno Consalvo; Chiara Sarlo; Consuelo Conti; Giovanna De Santis; Eleonora De Bellis; Ambra Di Veroli; Patrizia Palomba; Cristina Attrotto; Annagiulia Zizzari; Giovangiacinto Paterno; Maria Teresa Voso; Giovanni Del Poeta; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

Review 8.  Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Authors:  Federico Mosna; Debora Capelli; Michele Gottardi
Journal:  J Clin Med       Date:  2017-06-03       Impact factor: 4.241

9.  Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia.

Authors:  Fu-Jia Liu; Wen-Yan Cheng; Xiao-Jing Lin; Shi-Yang Wang; Tian-Yi Jiang; Ting-Ting Ma; Yong-Mei Zhu; Yang Shen
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

10.  Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.

Authors:  Michele Malagola; Cristina Skert; Giuseppina Ruggeri; Alessandro Turra; Rossella Ribolla; Valeria Cancelli; Federica Cattina; Elisa Alghisi; Simona Bernardi; Simone Perucca; Andrea Di Palma; Erika Borlenghi; Chiara Pagani; Giuseppe Rossi; Luigi Caimi; Domenico Russo
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.